Who are FORSTEO's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): teriparatide and alendronate, Teriparatide (rDNA origin), teriparatide and raloxifene, rhPTH (1-84), Teriparatide (Forteo), Parathyroid Hormone (PTH).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/forsteo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FORSTEO — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FORSTEO (FORSTEO) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parathyroid hormone analog. Area: Endocrinology / Bone Metabolism.

marketed Parathyroid hormone analog PTH1 receptor Endocrinology / Bone Metabolism Biologic Live · refreshed every 30 min

Target snapshot

FORSTEO (FORSTEO) — Shenzhen Salubris Pharmaceuticals Co., Ltd.. Forsteo (teriparatide) is a recombinant human parathyroid hormone analog that stimulates bone formation by activating PTH1 receptors on osteoblasts.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FORSTEO TARGET	FORSTEO	Shenzhen Salubris Pharmaceuticals Co., Ltd.	marketed	Parathyroid hormone analog	PTH1 receptor
teriparatide and alendronate	teriparatide and alendronate	Medical University of Vienna	marketed	Combination therapy: PTH analog + bisphosphonate	PTH1 receptor (teriparatide); farnesyl pyrophosphate synthase (alendronate)
Teriparatide (rDNA origin)	Teriparatide (rDNA origin)	Bio Sidus SA	marketed	Parathyroid hormone analog	PTH1 receptor (PTHR1)
teriparatide and raloxifene	teriparatide and raloxifene	Medical University of Vienna	marketed	Combination therapy: PTH analog and selective estrogen receptor modulator (SERM)	PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene)
rhPTH (1-84)	rhPTH (1-84)	Shire	marketed	PTH1 receptor agonist	PTH1 receptor
Teriparatide (Forteo)	Teriparatide (Forteo)	M.D. Anderson Cancer Center	marketed	Parathyroid hormone analog	PTH1 receptor (parathyroid hormone 1 receptor)
Parathyroid Hormone (PTH)	Parathyroid Hormone (PTH)	Takeda	marketed	Peptide hormone / PTH1 receptor agonist	PTH1 receptor (PTHR1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parathyroid hormone analog class)

Bio Sidus SA · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Pfenex, Inc · 1 drug in this class
Shenzhen Salubris Pharmaceuticals Co., Ltd. · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FORSTEO — Competitive Intelligence Brief. https://druglandscape.com/ci/forsteo. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing